Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prevention of Bone Metastasis in Stage III NSCLC
NCT00172042Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2005
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoints: Progression-Free Survival at 24 months and Percentage of Participants With Progression-Free Survival Events at 24 months. Started Mar 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00172042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172042.